Biosimilars for the management of rheumatoid arthritis: economic considerations

Gulàcsi, László; Brodszky, Valentin; Baji, Petra; Kim, Ho Ung; Kim, Su Yeon; Cho, Yu Young; Péntek, Márta

doi:10.1586/1744666x.2015.1090313

Cited by 88 publications

(60 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BIA analyses are limited in the literature, both in general [34] and with respect to second-generation biosimilars [12]; therefore, the present study represents a valuable addition to the current knowledge base. In 2014, a systematic literature review identified a total of 17 EU BIA publications across all therapy areas [71].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries

et al. 2017

Self Cite

View full text Add to dashboard Cite

IntroductionNew biosimilars of monoclonal antibodies are anticipated to bring significant cost savings and increase access to treatment. The rituximab biosimilar CT-P10 has recently been approved in Europe in all indications held by reference rituximab (RTX), including rheumatoid arthritis, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia. We analyzed the budgetary impact of the introduction of CT-P10 into the European Union (EU) for use in patients with rheumatoid arthritis and cancer diagnoses, using a budget impact analysis model.MethodsThe model used a base case scenario in which the 1-year uptake of CT-P10 was estimated at 30%, and the cost of CT-P10 was assumed to be 70% of the cost of RTX. A second 1-year scenario was also modeled, in which the market share of CT-P10 was assumed to be 50% (scenario 2). Finally, 3-year time horizon outcomes were calculated, in which the market share of CT-P10 was assumed to be 30%, 40%, and 50% in the first, second, and third years, respectively.ResultsIn the base case scenario, the introduction of CT-P10 was associated with projected savings of €90.04 million in the first year, which would allow 7531 additional patients to access rituximab treatment. This was equivalent to a 6.4% increase in the number of rituximab-treated patients. In scenario 2, budget savings were €150.10 million, with a total of 12,551 additional patients able to access rituximab, equivalent to a 10.7% increase. Over a 3-year time horizon, projected budget savings were approximately €570 million, equating to 47,695 additional patients able to access rituximab.ConclusionsThe model predicted that the introduction of CT-P10 in the EU will be associated with significant budget savings, the reallocation of which will enable many more patients to access rituximab treatment. This is likely to have a significant impact on health gains at patient and societal levels. Funding: CELLTRION Healthcare Co., Ltd. sponsored the development and analysis of the budget impact analysis model.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-017-0522-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

“…All of these diseases have significant financial impacts on global healthcare systems. For example, RA is a chronic, progressive disease associated with significant direct and indirect costs to society [12, 13]. As the population ages, RA becomes an increasing burden globally.…”

Section: Introductionmentioning

confidence: 99%

The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…After the expiry of the patent protection of originator biological molecules, their less costly alternatives, biosimilars can enter the market with the promise of savings in the healthcare budget or enabling better patient access to biological treatment (Gulácsi et al 2015). Biosimilars are developed to be similar to already authorized reference biological medicines.…”

Section: Introductionmentioning

confidence: 99%

Economic aspects of biosimilar competition in Hungary — The treatment of rheumatic disorders

Zrubka

2017

Soc Ec

View full text Add to dashboard Cite

Biologicals are the fastest growing segment of the global pharmaceutical market, reaching 199 billion USD sales per year with 9.8% 10-year compound annual growth rate (CAGR). Being less costly, yet equally efficacious and safe alternatives to originator reference products, biosimilars drive competition, promise budget savings and the opportunity for better patient-access. This paper examines the key factors and players of biosimilar competition in rheumatology in Hungary. Due to the scarcity of data, the total yearly expenditure on biologicals could only be estimated from different data sources. In 2015 the estimated expenditure on biologicals was around 100 billion HUF. In rheumatology indications the expenditure on biologicals was 10 (8.9-11.2) billion HUF, and the average annual net treatment cost was 1.2 (1.06-1.34) million HUF / per patient / year. The magnitude of societal benefits in terms of budget savings and health gains may result from the joint effort of policy makers, funders, physicians and patients. In rheumatology indications, biosimilar utilization could be increased by a policy supporting physician-driven interchange of the reference product to biosimilars. Also, creating a physician inventive system for broader use should be considered in order to realize the full economic advantages of biosimilars and contribute to sustainable healthcare financing in Hungary. JEL: I11

show abstract

“…Several reviews have emphasised potential cost savings from the use of biosimilars,16 17 and some budget impact analyses were performed to quantify these cost reductions. Haustein et al showed that the use of biosimilars in Europe was expected to result in overall cost savings of €11.8 billion to €33.4 billion between 2007 and 2020, and of €2.9 billion to €6.3 billion in France only 18.…”

Section: Introductionmentioning

confidence: 99%

Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?

Beck

Michel

et al. 2016

Eur J Hosp Pharm

View full text Add to dashboard Cite

ObjectivesBiosimilar infliximab, the first similar biological medicinal product containing monoclonal antibodies to be commercialised, is likely to contribute to a significant reduction in healthcare costs. We aimed to assess the cost savings potential over 1 year of the use of biosimilar infliximab for the treatment of rheumatoid arthritis (RA) patients in Alsace and in France, in a real-life setting.MethodsThe analysis was based on a previously conducted observational study which evaluated the annual cost of the care of patients with RA treated with biological therapies in 2012 in Alsace. Average annual costs to manage RA patients were calculated, taking into account the decrease in the retail price between 2012 and 2015 (as given in the official national price list) and the local negotiated price for biosimilar infliximab. Annual cost savings for different biosimilar prescription scenarios were calculated using 2015 prices.ResultsManagement of RA patients with biosimilar infliximab was significantly cheaper than with adalimumab or etanercept (€11 907 vs €12 981 and €13 551, respectively). The projected annual cost savings reached €13.6 million nationally, if all adult RA patients treated with the originator infliximab switched to the biosimilar drug. These savings, if fully reallocated for the treatment of RA, would enable the treatment of 1141 additional patients.ConclusionsThe study showed a positive financial impact of introducing biosimilar infliximab for the treatment of RA patients in France. Such savings could contribute to improved patient care by allowing more patients to be treated without more money being spent.

show abstract

Biosimilars for the management of rheumatoid arthritis: economic considerations

Cited by 88 publications

References 54 publications

The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries

The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries

Economic aspects of biosimilar competition in Hungary — The treatment of rheumatic disorders

Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?

Contact Info

Product

Resources

About